Discordant Clinical and Microbiological Outcomes Are Associated With Late Clinical Relapse in Clinical Trials for Complicated Urinary Tract Infections.

Kadry, Nadia; Natarajan, Mukil; Bein, Edward; Kim, Peter; Farley, John

Kadry, Nadia; Natarajan, Mukil; Bein, Edward; Kim, Peter; Farley, John.

Afiliación

Kadry N; Office of Infectious Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Natarajan M; Office of Infectious Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Bein E; Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Kim P; Office of Infectious Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Farley J; Office of Infectious Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Clin Infect Dis ; 76(10): 1768-1775, 2023 05 24.

Article en En | MEDLINE | ID: mdl-36625164

Asunto(s)

Infecciones Urinarias; Humanos; Antibacterianos/uso terapéutico; Recurrencia; Infecciones Urinarias/microbiología

Palabras clave

antibacterial drug development; clinical trials; endpoint; urinary tract infection

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones Urinarias Tipo de estudio: Clinical_trials / Guideline / Risk_factors_studies Límite: Humans Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google